Finance

Lists
Why is SABS up 8,47%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
3,20 US$
+8,47%
(+0,25) 1D
3,20 US$
0,00% (0,00)
After hours
Closed: 18 ნოე, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
2,96 US$
High
3,32 US$
Low
2,95 US$
Mkt. cap
288,28 მლნ.
Avg. vol.
682,51 ათ.
Volume
137,00
52-wk high
5,15 US$
52-wk low
2,44 US$
EPS
-0,93 US$
Beta
0,67
Shares outstanding
90,09 მლნ.
No. of employees
86
Open
2,96 US$
High
3,32 US$
Low
2,95 US$
Mkt. cap
288,28 მლნ.
Avg. vol.
682,51 ათ.
Volume
137,00
52-wk high
5,15 US$
52-wk low
2,44 US$
EPS
-0,93 US$
Beta
0,67
Shares outstanding
90,09 მლნ.
No. of employees
86
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
Headquartersმაიამი-ბიჩი, ფლორიდა, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current 3,20 US$
15,00 US$ (+368,75%)
Average
13,25 US$ (+314,06%)
Lowest
11,00 US$ (+243,75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
14,00 US$
+337,5%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
11,00 US$
+243,8%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
15,00 US$
+368,8%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
13,00 US$
+306,2%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
10,00 US$
+212,5%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
16,00 US$
+400%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
6,00 US$
+87,5%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
14,00 US$
+337,5%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
11,00 US$
+243,8%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
15,00 US$
+368,8%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
13,00 US$
+306,2%
04/02/2026
Michael Yee
UBS
Buy
Maintained
7,00 US$
+118,7%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
-
-
-
-
Cost of goods sold
9,73 მლნ.
13,40 მლნ.
16,17 მლნ.
18,08 მლნ.
Cost of revenue
9,73 მლნ.
13,40 მლნ.
16,17 მლნ.
18,08 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,04 მლნ.
6,60 მლნ.
7,20 მლნ.
7,82 მლნ.
Operating expense
6,04 მლნ.
6,60 მლნ.
7,20 მლნ.
7,82 მლნ.
Total operating expenses
15,77 მლნ.
20,00 მლნ.
23,38 მლნ.
25,90 მლნ.
Operating income
-15,77 მლნ.
-20,00 მლნ.
-23,38 მლნ.
-25,90 მლნ.
Other non operating income
-1,73 მლნ.
144,40 ათ.
-761,00 ათ.
1,99 მლნ.
EBT including unusual items
-16,86 მლნ.
-18,87 მლნ.
-22,49 მლნ.
-22,30 მლნ.
EBT excluding unusual items
-16,86 მლნ.
-18,87 მლნ.
-22,49 მლნ.
-22,30 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16,86 მლნ.
-18,87 მლნ.
-22,49 მლნ.
-22,30 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,41
-
-0,28
-0,26
Interest and investment income
700,74 ათ.
1,05 მლნ.
1,71 მლნ.
1,61 მლნ.
Interest expense
-63,46 ათ.
-62,74 ათ.
-62,00 ათ.
-
Net interest expenses
637,28 ათ.
984,45 ათ.
1,65 მლნ.
1,61 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,01 მლნ.
-19,25 მლნ.
-22,54 მლნ.
-25,08 მლნ.
Gain or loss from assets sale
-
-
-
-66,00 ათ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები